Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 18: Line 18:


===Age===
===Age===
*Patients of all age groups may develop favism (acute hemolytic anemia from eating fava beans ) but more often and severe in childern   
*Patients of all age groups may develop [[favism]] (acute [[hemolytic anemia]] from eating fava beans ) but more often and severe in childern   


===Race===
===Race===
Line 25: Line 25:
*
*
===Gender===
===Gender===
*Men are more commonly affected by G6PD deficiency than women, because it is an X-linked recessive disorder.  
*Men are more commonly affected by G6PD deficiency than women, because it is an [[X-linked recessive]] disorder.  


===Region===
===Region===
Line 33: Line 33:
{{Reflist|2}}
{{Reflist|2}}


{{WH}}
{{WS}}
[[Category: (name of the system)]]
[[Category: (name of the system)]]
{{Glucose-6-phosphate dehydrogenase deficiency}}
{{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.D.]] [mailto:psingh13579@gmail.com]
Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How to Edit a Page|here]]  to learn about editing.
==Overview==
==Epidemiology and Demographics==
* G6PDD is said to be the most common enzyme deficiency disease in the world, affecting approximately 400,000,000 people globally.<ref>http://www.rddiagnostics.com/g6pd_faq.htm</ref>
* A side effect of this disease is that it confers protection against [[malaria]], in particular the form of [[malaria]] caused by ''[[Plasmodium falciparum]]'', the most deadly form of [[malaria]].
* A similar relationship exists between [[malaria]] and [[sickle-cell disease]]. An explanation is that cells infected with the ''Plasmodium'' parasite are cleared more rapidly by the [[spleen]]. This phenomenon might give [[G6PD deficiency]] carriers an evolutionary advantage.
==References==
{{reflist|2}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
[[Category:Disease]]
[[Category:Disease]]
[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Mature chapter]]
[[Category:Mature chapter]]
[[Need content]]

Revision as of 15:50, 27 August 2018

Glucose-6-phosphate dehydrogenase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Glucose-6-phosphate dehydrogenase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics

CDC on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics

Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics in the news

Blogs on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics

Directions to Hospitals Treating Glucose-6-phosphate dehydrogenase deficiency

Risk calculators and risk factors for Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahda Alihashemi M.D. [2]

Overview

Epidemiology and Demographics

Incidence

  • The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
  • In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.

Prevalence

  • G6PD deficiency is affecting 400 million people worldwide. [1]

Case-fatality rate/Mortality rate

  • G6PD deficiency resulted in 4,100 deaths in 2013 and 3,400 deaths in 1990[2]

Age

  • Patients of all age groups may develop favism (acute hemolytic anemia from eating fava beans ) but more often and severe in childern

Race

  • African, Middle Eastern and South Asian people are affected the most.

Gender

  • Men are more commonly affected by G6PD deficiency than women, because it is an X-linked recessive disorder.

Region

  • The majority of G6PD deficiency cases are reported in African, Middle Eastern and South Asian people. [3]

References

  1. Mason PJ, Bautista JM, Gilsanz F (September 2007). "G6PD deficiency: the genotype-phenotype association". Blood Rev. 21 (5): 267–83. doi:10.1016/j.blre.2007.05.002. PMID 17611006.
  2. "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 385 (9963): 117–71. January 2015. doi:10.1016/S0140-6736(14)61682-2. PMC 4340604. PMID 25530442.
  3. Beutler E (January 1991). "Glucose-6-phosphate dehydrogenase deficiency". N. Engl. J. Med. 324 (3): 169–74. doi:10.1056/NEJM199101173240306. PMID 1984194.